Abstract BRCA2 and PALB2 function together in the Fanconi anemia (FA)-Breast Cancer (BRCA) pathway. Mono-allelic and bi-allelic BRCA2 and PALB2 mutation carriers share many clinical characteristics. Mono-allelic germline mutations of BRCA2 and PALB2 are risk alleles of female breast cancer and have also been reported in familial pancreatic cancer, and bi-allelic mutations cause a severe form of Fanconi anemia. In view of these similarities, we investigated whether the prevalence of PALB2 mutations was increased in breast cancer families with the occurrence of BRCA2 associated tumours other than female breast cancer. PALB2 mutation analysis was performed in 110 non-BRCA1/2 cancer patients: (a) 53 ovarian cancer patients from female breast-and/or ovarian cancer families; (b) 45 breast cancer patients with a first or second degree relative with pancreatic cancer; and (c) 12 male breast cancer patients from female breast cancer families. One truncating PALB2 mutation, c.509_510delGA, resulting in p.Arg170X, was found in a male breast cancer patient. We conclude that germline mutations of PALB2 do not significantly contribute to cancer risk in non-BRCA1/2 cancer families with at least one patient with ovarian cancer, male breast cancer, and/or pancreatic cancer.
Introduction
Breast cancer (BC) is a major cause of cancer-related deaths among women. At present, 20% of familial breast cancer is explained by germline mutations in known breast cancer predisposition genes. The high risk breast cancer susceptibility genes BRCA1 and BRCA2 account for the majority of these causative mutations [1] . Heterozygous BRCA1 mutation carriers are at high risk of female breast cancer and ovarian cancer. Heterozygous BRCA2 mutation carriers are at high risk of female breast cancer, and several other cancers. Estimated cumulative risks from several studies varies in BRCA2 female carriers from 14-24% for ovarian cancer, and 3% for pancreatic cancer [2, 3] . In male BRCA2 carriers, cancer risk is estimated around 6-7% for pancreatic cancer and male breast cancer [2, 3] .
One of the pathways often involved in breast cancer susceptibility is the Fanconi anemia (FA)-Breast Cancer (BRCA) pathway [4] . At present, 13 FA genes have been identified. FA is an autosomal recessive or X-linked inherited disorder with hypersensitivity to DNA crosslinking agents and chromosomal instability at the cellular level. Clinically FA is characterized by congenital malformations, bone marrow failure and predisposition to cancer, primarily acute myeloid leukemia and squamous cell carcinoma.
BRCA2 and PALB2 are two of the currently known FA genes. PALB2 (FANCN), which is named to its function as a partner and localizer of BRCA2 (FANCD1) [5] [6] [7] . PALB2 has been shown to enable the BRCA2 protein to function in DNA repair by stabilization in nuclear foci [8] .
BRCA2 and PALB2, also share additional clinical features, namely an increased risk to childhood solid tumours in bi-allelic mutation carriers and an increased risk to female breast cancer (RR of 8-10 and 2, respectively) and pancreatic cancer in mono-allelic mutation carriers [1, 7, 9, 10] .
In view of the overlapping phenotype and function of BRCA2 and PALB2, we hypothesized that PALB2 mutations may preferentially associate with BRCA1/2 negative tested cancer families with a BRCA2-like cancer phenotype, namely families in which BRCA2-associated tumours other than female breast cancer are observed. We screened PALB2 in a cohort of 110 cancer patients from non-BRCA1/2 families selected for ovarian cancer, pancreatic cancer and male breast cancer.
The prevalence of PALB2 mutations was low in our enriched non-BRCA1/2 cohort since only one truncating mutation was found.
Materials and methods

Cohort
A total of 110 cases from independent families referred to the clinical genetics department of the VU Medical Center in Amsterdam between 1994 and 2008 were analysed for PALB2 mutations and large deletions. All cases were excluded for mutations in BRCA1 and BRCA2 genes. Individuals with a BRCA2 associated tumour were selected for this study on the basis of being affected with: (a) ovarian cancer (n = 53) with a family history of female breast-and/or ovarian cancer (age at diagnosis of ovarian cancer ranged from 22-76 years, average 54 years), (b) female breast cancer with a first or second degree relative with pancreatic cancer (n = 45, age at diagnosis of breast cancer ranged from 23-74 years, average 43 years) and (c) male breast cancer with a family history of female breast cancer (n = 12, age at diagnosis of male breast cancer ranged from 32-77 years, average 54 years).
Of the 53 women with ovarian cancer, 16 had a personal history of both ovarian cancer and breast cancer. Of the 45 breast cancer cases, eight were bilaterally affected.
Mutation carrier probability in our cohort was scored with two manual BRCA1/2 risk assessment models. Of our selected cases, 60 and 39% scored a C15% and C20% probability of being carrier of a BRCA1/2 mutation according to Myriad II (Frank model), respectively (www.myriadtests.com). Since this model does not account for relatives with breast cancer above 50 and/or relatives with pancreatic cancer, we also scored the families with the Manchester model, which appears to be more predictive for BRCA2 mutations [11] . The total Manchester score was C15 or C20 in 72 and 43% of the selected families, respectively.
All cases gave informed consent to search for new cancer susceptibility genes.
Sequencing and MLPA
The presence of germline mutations in PALB2 was evaluated by direct sequencing of the entire coding region and intron-exon boundaries on genomic DNA isolated from whole blood. Primer pairs that were used have been previously described [6] .
To determine the segregation of the c.509_510delGA mutation in the family, a nested PCR within exon 4 of PALB2 was performed using the following forward (F) and reverse (R) primer sequences surrounding the mutation; F 5 0 -GAA GCA GCA GAA GAG GAC AT-3 0 and R 5 0 -TTC AGT TAC TGG TGA TCT AGC-3 0 . DNA was isolated from whole blood from one sister, and DNA was isolated from paraffin embedded normal and tumour tissue from the deceased sister (Fig. 1) .
The presence of large deletions in the PALB2 gene was analyzed by Multiplex Ligation-dependent Probe Amplification (MLPA) using the MLPA P057 kit of MRC-Holland as previously described [12] . As a positive control, genomic DNA from the previously described PALB2 FA patient EUFA1341 was included in the analysis [6] .
All coding exons (including intron/exon boundaries) of BRCA1 and BRCA2 were screened for mutations by a combination of denaturing gradient gel electrophoresis and DNA sequencing. In addition, BRCA1 was tested for exon deletions and duplications by MLPA.
Results
Sequence analysis of the PALB2 gene in a selected cohort of 110 non-BRCA1/2 cases (for selection see Materials and Methods) revealed a frameshift mutation in exon 4, c.509_510delGA. The mutation is predicted to result in p.Arg170X at the protein level and was identified in one of the male breast cancer cases (Fig. 1 ). The male patient had breast cancer and a melanoma in situ, both at age 62 years. The breast cancer was a grade 3 invasive ductal carcinoma, which was positive for Estrogen (ER) and Progesteron (PR), and negative for Her2. He died at the age of 64 years. The melanoma in situ was located on his back.
The PALB2 mutation was not present in DNA isolated from paraffin-embedded tumour and normal breast tissue from the deceased sister with lobular breast cancer (ER negative, PR negative and Her2 positive). DNA of the mother and one of the affected sisters with breast cancer was not available. Although not considered as a BRCAassociated tumour, we did test whole blood DNA from the sister with uterine carcinoma at age 77 years. She did not carry the mutation either.
Seven different amino acid substitutions were found. All are known SNP's and six have been previously described to occur frequently and in equal percentages in affected breast cancer cases and controls [13] . One of these variants, the L939W, is predicted (although with low confidence) to possibly affect the protein function in three in silico tests (PolyPhen, SIFT and align GVGD). However, this variant was found in three previous studies including the large breast cancer case control study by Rahman et al. [13] [14] [15] . Therefore all missense variants are unlikely to have a significant pathogenic effect (Table 1) . Intronic and synonymous variants which are not predicted to affect splicing are unlikely to have any clinical relevance ( Table 1) .
The cohort was also analyzed for larger deletions using MLPA in PALB2. No alterations in the PALB2 gene were identified by MLPA in any of the 110 cases.
Discussion
The chance of finding a cancer predisposing allele generally increases when families harbour increasing numbers of patients, or multiple phenotypes associated with the risk allele. For example the mutation rate in the high risk breast cancer predisposing genes BRCA1 and BRCA2 increases dramatically in an individual when multiple cases of early onset breast cancer, or additionally ovarian cancer occurs within the family (www.myriadtests.com). Likewise, for the low risk breast cancer predisposing allele CHEK2*1100-delC the chance of finding this allele increases from 1, 3, to 5-6% in the Dutch population, in sporadic breast cancer, and in familial breast cancer or in bilateral breast cancer [16, 17] . Statistical modelling showed that this was best explained by a polygenic model in which multiple low risk alleles increased cancer risk in a multiplicative way [16] .
We therefore hypothesized that the frequency of mutations in the moderate risk breast cancer predisposing gene PALB2 may increase in case additional cancer phenotypes are present within the family.
We screened a cohort of 110 non-BRCA1/2 cancer patients, including 53 ovarian cancer patients, 45 female breast cancer patients with a first or second degree relative with pancreatic cancer and 12 male breast cancer patients, for the presence of truncating mutations in the PALB2 gene by sequencing and MLPA analysis. Direct sequencing revealed one truncating mutation (p.Arg170X) in a male breast cancer patient, which was not present in DNA from one sister with breast cancer and in the sister with uterine cancer (Fig. 1) .
MLPA did not detect any deletion in our cohort. Previously we already described that exon deletions and duplications in PALB2 were not observed in a large cohort of Dutch familial breast cancer patients [12] .
The PALB2 mutation frequency in this enriched cohort with BRCA2 associated tumours was not increased when compared to the described prevalence of approximately 1% in familial non-BRCA1/2 breast cancer cohorts [13, 14, 18] .
Currently, there is evidence that PALB2 is involved in predisposition to breast cancer and familial pancreatic cancer, but this is lacking for other cancers, in particular male breast cancer and ovarian cancer.
In total, 77 PALB2 mutation-positive cases have been identified mainly in familial or early onset breast cancer cohorts from different populations [13, 15, [18] [19] [20] [21] [22] [23] [24] [25] . Of the 77 described PALB2 mutation cases, 52 are carrier of the 1592delT Finnish founder mutation, which could influence the currently known phenotype [19, 24, 26] . The selection criteria of these previous breast cancer studies varied, but most studies included BRCA1/2 mutation negative early onset breast cancer patients with diagnosis under 50 years or breast cancer patients from families with first or second degree relatives affected with breast-or ovarian cancer in unknown numbers.
Ovarian cancer is the most prevalent cancer type in BRCA2 mutated families next to breast cancer. Our cohort included 53 familial ovarian cancer patients, but no mutation was found in PALB2 in any of these cases. Recently, a Polish study tested a set of sporadic 70 ovarian carcinomas for PALB2 mutations [27] . Remarkably they found the same mutation (c.509_510delGA) as we did. After this finding, they analyzed additional cohorts for the prevalence of the c.509_510delGA mutation: a cohort of 339 unselected tumour fragments of ovarian carcinomas; a cohort of 982 breast cancer patients, of which 648 familial cases; and 1310 controls. They identified this mutation in 2 out of 339 ovarian cancers (0.6%), 4 out of 982 breast cancers (0.4%; all familial cases), and 1 out of 1,310 controls (0.08%). One of the ovarian cancer patients appeared to carry a pathogenic BRCA2 mutation. Most of the cancer cases included in this study were not or only partially analyzed for mutations of BRCA1 and BRCA2. Since the c.509_510delGA mutation was recurrently found in the Polish population, it was suggested to be a possible PALB2 founder mutation in central Poland. Till now all mutations, except the Finnish PALB2 founder mutation, were unique. We identified the c.509_510delGA mutation in a male breast cancer patient from Dutch ancestry. The c.509_510delGA mutation may therefore either represent a recurrent mutation or a founder mutation with a much larger geographical distribution than central Poland.
The data of this Polish study and our data suggest that PALB2 has only a marginal role in ovarian cancer predisposition.
Pancreatic cancer risk related to PALB2 was evaluated in familial (n = 197) and in sporadic pancreatic cancer cases (n = 114) [10, 28] . In total, five PALB2 mutation carriers with pancreatic cancer were identified. All but one of these five families were also affected with breast cancer and the only two female PALB2 mutation carriers both suffered from pancreatic cancer and breast cancer. We analyzed 45 breast cancer patients with a first or second degree relative with pancreatic cancer. However, no truncating mutation was found.
The only truncating mutation (p.Arg170X) in our cohort was found in one out of 12 male breast cancers patients. This confirms the results of a previous breast cancer study in which one out of 15 female breast cancer patients with male breast cancer in the family contained a mutation (6.7%) [13] . Three previous studies have reported on the frequency of PALB2 mutations in male breast cancer. In 141 unselected Finnish male patients, the Finnish PALB2 founder mutation was not found [19] . The whole coding sequence of PALB2 was analyzed in 25 Australian male breast cancer cases from breast cancer families, and in 97 BRCA1/2 negative male breast cancer cases from Italy, of which 26% had a positive family history of breast and/or ovarian cancer in a first degree relative. No truncating mutations were found in either study [29, 30] .
Overall, these data do not suggest a significant relation of PALB2 mutations and male breast cancer.
With respect to various other cancers, the Finnish PALB2 founder mutation was tested in two independent studies including in total 476 unselected colorectal cancer cases, 1223 unselected prostate cancer cases, and 342 familial prostate cancer cases [19, 26] . Two familial and two unselected prostate cancer cases carried the founder mutation (0.6 and 0.16% respectively). Of note, the frequency of the Finnish PALB2 founder mutation is 0.2% in the general (Finnish) population. Tischkowitz et al. sequenced PALB2 in 95 prostate cancer families from American descent and found no truncating mutations [31] . Overall, these data suggest that these cancer types are not significantly associated with mutations in PALB2. Cancer types that are still disputed to be associated with BRCA2, like prostate cancer, colonic cancer, melanoma, and stomach cancer were left out of our cohort.
To conclude there is no enrichment for the prevalence of germline heterozygous PALB2 mutations in familial non-BRCA1/2 ovarian cancer patients, breast cancer patients with a familial history of pancreatic cancer, and familial non-BRCA1/2 male breast cancer patients. Therefore diagnostic testing of PALB2 in non-BRCA1/2 families is not indicated in these settings.
